ReviewAlzheimer's & dementia (New York, N. Y.)
Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans.
Review in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Engendering trustworthiness in the community: Strategies for researchers.Journal of Alzheimer's disease : JAD · 2026Article
- Barriers and facilitators to recruitment, engagement, and retention of underrepresented populations in dementia prevention research: a scoping review.The journal of prevention of Alzheimer's disease · 2026Article
- Article
- Systems biology of Alzheimer's Disease: a scoping review of key pathways and mechanisms.Molecular neurodegeneration · 2026Article
- Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations.Current cardiology reports · 2025Review
- Study partners' views on remuneration in longitudinal Alzheimer's disease research.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025Article
- Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.BMJ (Clinical research ed.) · 2025Article
- Promoting Diversity through an Understanding of Barriers and Drivers for Inclusive Clinical Trials.Therapeutic innovation & regulatory science · 2025Article
- A multiperspective investigation of the underrepresentation of minoritized ethnic participants in dementia research and proposed strategies to improve inclusive recruitment practices.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Reviewing and Advocating for Data Disaggregation in Aging-Related Health Research: NIA Grants and Recommendations for Equity.The Gerontologist · 2025Article
- Improving participants' recruitment in dementia-related studies on social media through colloquial language in Lima, Peru.Dementia & neuropsychologia · 2025Article
- A Mindfulness-Based Lifestyle Intervention for Dementia Risk Reduction: Protocol for the My Healthy Brain Feasibility Randomized Controlled Trial.JMIR research protocols · 2024Article
- Community recruitment of underrepresented populations to the AHEAD 3-45 preclinical AD trial using novel partnerships with nursing and community-based organizations: Lessons and outcomes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Underrepresented and Underserved Populations in Neurological Research.Seminars in neurology · 2024Article
- Portable Accessible MRI in Dementia Research: Ethical Considerations About Research Representation and Dementia-Friendly Technology.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2024Article
- Hearing loss and cognitive decline: Prioritizing equity in a world in which hearing health matters.Alzheimer's & dementia (New York, N. Y.)Article
- Article
- Unforgettable: The power of community in the pursuit of health equity for Alzheimer's disease and other dementia.Alzheimer's & dementia (New York, N. Y.)Article
- How can Alzheimer's disease blood-based biomarkers reach clinical practice?Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Researcher photographs in recruitment materials to increase willingness to participate in brain health research.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Introduction: Black Americans are disproportionately burdened by Alzheimer's disease (AD) relative to other racial groups in the United States and continue to be underrepresented in AD clinical trials. This review explores the primary barriers for participation in clinical trials among Black Americans and provides literature-based recommendations to improve the inclusion of Black Americans in AD clinical trials. Methods: We searched electronic databases and gray literature for articles published in the United States through January 1, 2023, ultimately identifying 26 key articles for inclusion. Results: Barriers to participation in clinical trials for Black Americans are rooted in social determinants of health, including access to quality education and information, access to health care, economic stability, built environment, and community context. Best practices to improve the inclusion of Black Americans in clinical trials require pharmaceutical companies to adopt a multifaceted approach, investing in innovative strategies for site selection, development of local partnerships, outreach, and education. Discussion: While multisectoral action must occur to effectively address the disproportionate burden of AD on Black Americans, the pharmaceutical industry has an important part to play in this space due to their central role in product development and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.